AMSTERDAM, the Netherlands – Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the United States. Tyruko® is the first and only FDA-approved biosimilar of natalizumab for the treatment of relapsing forms of multiple sclerosis (MS), and...
treatment News
Gdańsk, Poland – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it has published data in International Immunopharmacology which suggest that PD-1+ T-cells are a dependable biomarker for efficacy in pediatric early-onset Type-1 diabetes (T1D) patients,...
Gdańsk, Poland – PolTREG S.A., a clinical-stage biotechnology company in Europe developing cell therapies for use in a wide range of autoimmune diseases, announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO), covering the manufacturing of T-regulatory cells (T-reg) to treat Type-1 diabetes...
SOUTH SAN FRANCISCO, Calif. — Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced updated efficacy and safety data from its Phase 2 clinical trial of picoplatin in patients with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The data demonstrate that picoplatin in combination with...
LONDON, UK – Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a novel...
INGELHEIM AM RHEIN, Germany – Boehringer Ingelheim today announced new data from the global Phase III FIBRONEER™ program on nerandomilast, an investigational oral preferential PDE4B inhibitor, which is currently not approved for use. The new pooled analyses, the first to demonstrate a nominally significant reduction in risk of death across...
Posaconazole was non-inferior to voriconazole for the primary treatment of invasive aspergillosis, according to an international, randomized, double-blind, double-dummy, controlled non-inferiority trial published in the Lancet. Between October 25, 2013, and September 10, 2019, investigators randomly assigned 585 participants to receive either posaconazole or voriconazole. In the posaconazole group, 288 participants...
SAN DIEGO, CA — Poseida Therapeutics, Inc., a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today highlighted recent progress across the company’s cell and gene therapy portfolio and provided updates on anticipated upcoming milestones. “In 2023, we made...
SAN DIEGO, Calif. — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced new data from a subset of patients in an ongoing Phase 1 study of its lead program, P-BCMA-ALLO1. Results...
MELBOURNE, Australia – Neuren Pharmaceuticals Limited (ASX: NEU) has received clear and constructive guidance from the FDA Office of Neuroscience in pre-IND meetings for Phase 2 clinical trials of NNZ-2591 in Phelan-McDermid, Angelman and Pitt Hopkins syndromes. All three syndromes are serious neurological disorders that emerge in early childhood and have no...